Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers

Citation
Le. Gamadia et al., Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers, BLOOD, 98(3), 2001, pp. 754-761
Citations number
43
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BLOOD
ISSN journal
00064971 → ACNP
Volume
98
Issue
3
Year of publication
2001
Pages
754 - 761
Database
ISI
SICI code
0006-4971(20010801)98:3<754:DOCCTC>2.0.ZU;2-6
Abstract
During immunosuppression, cytomegalovirus (CMV) can reactivate and cause se rious clinical problems. Normally, abundant virus replication is suppressed by immune effector mechanisms. To study the interaction between CD8(+) T c ells and persisting viruses, frequencies and phenotypes of CMV-specific CD8 (+) T cells were determined in healthy individuals and compared to those in renal transplant recipients. In healthy donors, function of circulating vi rus-specific CD8(+) T cells, as measured by peptide-induced interferon gamm a (IFN-gamma) production, but not the number of virus-specific T cells enum erated by binding of specific tetrameric peptide/HLA complexes, correlated with the number of CMV-specific IFN-gamma -secreting CD4(+) helper T cells. Circulating CMV-specific CD8(+) T cells did not express CCR7 and may there fore not be able to recirculate through peripheral lymph nodes. Based on co expression of CD27 and CD45R0 most CMV-specific T cells in healthy donors a ppeared to be memory-type cells. Remarkably, frequencies of CMV-specific CD 8(+) T cells were significantly higher in immunosuppressed individuals than in healthy donors. In these patients CMV-specific cells predominantly had an effector phenotype, that is, CD45R0(+)CD27(-)CCR7(-) or CD45RA(+)CD27(-) CCR7(-) and contained both granzyme B and perforin. Our data show that In r esponse to immunosuppressive medication quantitative and qualitative change s occur In the CD8(+) T-cell compartment. These adaptations may be Instrume ntal to maintain CMV latency. (C) 2001 by The American Society of Hematolog y.